| Engineered promoters |
2023-1-20 |
2023-7-27 |
|
| Methods and compositions for treating epilepsy |
2023-1-13 |
2023-7-20 |
|
| Adeno-associated virus for therapeutic delivery to central nervous system |
2023-1-05 |
2023-7-20 |
|
| Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 … |
2022-12-27 |
2023-4-11 |
|
| Method for improving neurological function in mpsi and mpsii and other … |
2022-12-02 |
2023-2-14 |
|
| Engineered nucleic acid regulatory elements and methods and uses thereof |
2022-10-28 |
2023-5-04 |
|
| Antibodies and methods of using thereof |
2022-10-15 |
2023-4-20 |
|
| Recombinant adeno-associated viruses for targeted delivery |
2022-10-07 |
2023-4-13 |
|
| Recombinant adeno-associated viruses for cns tropic delivery |
2022-10-07 |
2023-4-13 |
|
| Compositions and methods for recombinant aav production |
2022-10-05 |
2023-4-13 |
|
| Auf1 combination therapies for treatment of muscle degenerative disease |
2022-7-19 |
2023-1-26 |
|
| Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2- … |
2022-7-10 |
2022-9-01 |
|
| Treatment of mucopolysaccharidosis iva |
2022-7-10 |
2022-9-01 |
|
| Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha- … |
2022-7-09 |
2022-9-01 |
|
| Treatment of ocular diseases with fully human post-translationally modified … |
2022-7-06 |
2022-10-12 |
|
| Methods for the treatment of epilepsy |
2022-6-30 |
2023-2-09 |
|
| Microdystrophin gene therapy constructs and uses thereof |
2022-5-25 |
2022-7-01 |
|
| Methods and compositions for treating epilepsy |
2022-5-16 |
2023-1-05 |
|
| Methods and compositions for treating epilepsy |
2022-5-16 |
2022-11-17 |
|
| Treatment of duchenne muscular dystrophy and combinations thereof |
2022-5-11 |
2022-11-17 |
|
| Novel aav vectors and methods and uses thereof |
2022-5-03 |
2022-12-08 |
|
| Microdystrophin gene therapy administration for treatment of dystrophinopathies |
2022-4-26 |
2022-11-03 |
|
| Injection of single stranded adeno-associated virus 9 or self-complementary … |
2022-4-22 |
2022-7-06 |
|
| Adeno-associated virus vector pharmaceutical composition and methods |
2022-4-04 |
2022-6-01 |
|
| Treatment of diabetic retinopathy with fully-human post-translationally … |
2022-2-24 |
2022-4-01 |
|
| Adeno-associated virus mediated gene transfer to central nervous system |
2022-2-21 |
2022-4-26 |
|
| Methods for preventing cardiac or skeletal defects in diseases including … |
2022-2-04 |
2022-8-11 |
|
| Gene therapy for neuronal ceroid lipofuscinoses |
2022-1-31 |
2023-9-14 |
|
| Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2- … |
2022-1-31 |
2022-8-18 |
|
| Gene therapy for neuronal ceroid lipofuscinoses |
2022-1-31 |
2022-8-04 |
|
| Improved production of recombinant polypeptides and viruses |
2022-1-21 |
2022-7-28 |
|
| Engineered nucleic acid regulatory element and methods of uses thereof |
2022-1-17 |
2022-3-01 |
|
| Tau-specific antibody gene therapy compositions, methods and uses thereof |
2021-12-29 |
2022-11-01 |
|
| COMPOSITIONS FOR GENE THERAPY OF SPECIFIC ANTIBODIES TO TAU, METHODS AND USES … |
2021-12-29 |
2023-4-05 |
|
| Method of producing a recombinant adeno-associated virus particle |
2021-12-16 |
2023-6-29 |
|
| Vectorized factor xii antibodies and administration thereof |
2021-10-29 |
2022-5-05 |
|
| Vectorized tnf-alpha antagonists for ocular indications |
2021-10-29 |
2022-5-05 |
|
| Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
2021-10-28 |
2023-9-06 |
|
| Vectorized anti-tnf-alfa antibodies for ocular indications |
2021-10-28 |
2023-9-06 |
|
| Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
2021-10-28 |
2022-5-05 |
|
| Fully-human post-translationally modified antibody therapeutics |
2021-10-20 |
2021-12-01 |
|
| Adeno-associated virus vector formulations and methods |
2021-10-12 |
2021-12-01 |
|
| Recombinant adeno-associated viruses for cns or muscle delivery |
2021-10-07 |
2022-4-14 |
|
| Adeno-associated viruses for ocular delivery of gene therapy |
2021-10-07 |
2022-6-02 |
|
| Recombinant adeno-associated viruses for cns or muscle delivery |
2021-10-07 |
2022-5-27 |
|
| Methods of size exclusion chromatography for the characterization of … |
2021-10-07 |
2021-12-01 |
|
| FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS HIGH VISCOSITY … |
2021-10-06 |
2023-1-04 |
|
| FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS GEL FORMULATIONS |
2021-10-06 |
2023-1-04 |
|
| Formulations for suprachoroidal administration such as high viscosity … |
2021-10-06 |
2023-5-25 |
|
| FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS FORMULATIONS WITH … |
2021-10-06 |
2023-1-04 |
|
| Gene therapy for ocular manifestations of cln2 disease |
2021-10-06 |
2022-4-14 |
|
| Formulations for suprachoroidal administration such as formulations with … |
2021-10-06 |
2022-8-01 |
|
| Formulations for suprachoroidal administration such as gel formulations |
2021-10-06 |
2022-4-14 |
|
| Recombinant adeno-associated viruses and uses thereof |
2021-10-03 |
2021-10-31 |
|
| Gene therapy for eye pathologies |
2021-9-29 |
2021-10-31 |
|
| Vectorized lanadelumab and administration thereof |
2021-9-15 |
2022-3-24 |
|
| Vectorized antibodies for anti-viral therapy |
2021-9-15 |
2022-3-24 |
|
| Methods and compositions for treating epilepsy |
2021-7-09 |
2023-2-23 |
|
| Compounds for use in the treatment of epilepsy |
2021-7-09 |
2022-1-13 |
|
| Gene therapy for neuronal ceroid lipofuscinoses |
2021-4-29 |
2021-6-30 |
|
| Method for measuring the infectivity of replication defective viral vectors and … |
2021-4-08 |
2021-5-31 |
|
| Compositions and methods for treating ocular disorders |
2021-3-18 |
2023-6-29 |
|
| Treatment of mucopolysaccharidosis iva |
2021-2-25 |
2021-3-08 |
|
| Scalable method for recombinant aav production |
2021-2-04 |
2021-3-25 |
|
| TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE II WITH RECOMBINANT HUMAN IDURONATE-2- … |
2021-1-28 |
2022-4-27 |
|
| TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY HUMAN GLYCOSYLATED α-L- … |
2021-1-20 |
2022-4-13 |
|
| Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha- … |
2021-1-14 |
2021-3-01 |
|
| Anion exchange chromatography for recombinant aav production |
2020-12-03 |
2021-1-31 |
|
| Microdystrophin gene therapy constructs and uses thereof |
2020-11-27 |
2021-6-03 |
|
| CONSTRUCTIONS FOR GENE THERAPY WITH MICRODYSTROPHIN AND THEIR USE |
2020-11-27 |
2022-2-23 |
|
| POST TRANSLATION MODIFIED FULLY HUMAN ANTI-VEGF Fab TREATMENT OF DIABETIC … |
2020-8-25 |
2022-1-12 |
|
| Compositions for treatment of wet age-related macular degeneration |
2020-8-18 |
2020-10-29 |
|
| THERAPEUTICS OF FULLY HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODIES |
2020-4-24 |
2021-10-27 |
|
| Methods of size exclusion chromatography for the characterization of … |
2020-4-10 |
2020-10-15 |
|
| RECOMBINANT ADENO-ASSOCIATED VIRUSES AND THEIR USES |
2020-4-03 |
2021-10-20 |
|
| GENE TREATMENT FOR EYE PATHOLOGIES |
2020-4-02 |
2021-10-20 |
|
| Fully-human post-translationally modified antibody therapeutics |
2020-4-01 |
2020-5-31 |
|
| Treatment of ocular diseases with fully-human post-translationally modified … |
2020-3-18 |
2020-5-31 |
|
| Treatment of ocular diseases with human post-translationally modified vegf-trap |
2020-3-05 |
2021-1-14 |
|
| TREATMENT OF MUCOPOLYSACARIDOSIS IVA |
2019-7-26 |
2021-3-03 |
|
| Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha- … |
2019-7-12 |
2019-9-26 |
|
| Systems and methods of spectrophotometry for the determination of genome … |
2019-4-27 |
2021-7-29 |
|
| Scalable clarification process for recombinant aav production |
2019-4-27 |
2021-3-10 |
|
| TREATMENT OF MUCOPOLISACARIDOSIS II WITH IDURONATE-2-SULFATASE (IDS) HUMAN … |
2018-4-13 |
2019-7-17 |
|
| TREATMENT OF MUCOPOLISACARIDOSIS I WITH a-L-IDURONIDASA (IDUA) HUMAN … |
2018-1-30 |
2019-5-02 |
|
| Treatment of ocular diseases with fully-human post-translationally modified … |
2017-4-14 |
2022-4-29 |
|
| Adeno-associated virus mediated gene transfer to the central nervous system |
2014-5-15 |
2014-11-20 |
|
| Transfert genique au systeme nerveux central a mediation par un virus adeno- … |
2014-5-15 |
2014-11-20 |
|